Compare Nuwellis Inc (NUWE) vs VF Corp (VFC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nuwellis Inc vs VF Corp — how do they compare? Nuwellis Inc trades at $0.68 (market cap $2.20M), while VF Corp trades at $15.06 (market cap $5.71B). The key difference: VF Corp is far larger — about 2595.5× Nuwellis Inc's market cap, and VF Corp pays a 2.48% dividend while Nuwellis Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Nuwellis Inc for 26 Days and VF Corp for 65 Days on average.
| NUWE | VFC | |
|---|---|---|
Market Cap | $2.20M | $5.71B |
Volume | 121,544 | 8,987,330 |
Sector | Health | Consumer Cyclical |
52-Week High | $146.65 | $21.55 |
52-Week Low | $0.68 | $12.62 |
Typical Hold Time | 26 Days | 65 Days |
Enterprise Value | -$1.52M | $10.00B |
Dividend Yield | — | 2.48% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NUWE trades at $0.6907, down 1.48% on the day, with a bearish technical signal from moving averages despite oversold RSI readings. The company reported revenue growth to $9M in 2026 but remains deeply unprofitable with a net income margin of -125.63%. Recent news highlights console sales growth and strategic expansions in pediatric and critical care markets.
The outlook is high-risk due to persistent losses and negative cash flow, though analyst sentiment is split with a 50% buy rating. Investment potential hinges on the company's ability to achieve profitability and scale its Aquadex platform, while risks include cash burn and competitive pressures in the medical device sector.
VFC trades at $15.00, up 4.31% today, showing recent volatility amid mixed earnings results. The stock maintains a bullish technical signal with strong moving average support, while fundamentals reveal declining revenue from $11.8B in 2022 to $9.5B in 2025 and negative net income of -$189.72M. Analyst consensus leans Hold with a $18.33 price target, representing 22% upside potential. Recent news highlights ongoing challenges with Vans brand performance despite strength in Outdoor segments.
VFC presents a turnaround opportunity with discounted valuation (P/S 0.61) but faces execution risks from brand-specific weaknesses. The company's deleveraging progress and dividend cut signal financial discipline, though sustained revenue growth remains critical for recovery. Near-term catalysts include Q3 2026 earnings and continued Outdoor segment momentum.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Nuwellis Inc
Nuwellis, Inc. is a medical device company focused on developing and commercializing fluid management solutions. The company's primary product is an ultrafiltration system used in hospitals to remove excess fluid from patients with fluid overload, often associated with conditions such as heart and kidney failure. Nuwellis aims to improve patient outcomes and reduce healthcare costs through its specialized, innovative therapies.
Read more on NUWE →About VF Corp
VF designs, produces, and distributes branded apparel and accessories. Its largest apparel categories include action sports, outdoor, and workwear. Its portfolio of about a dozen brands includes Vans, The North Face, Timberland, Supreme, and Dickies. VF markets its products in the Americas, Europe, and Asia-Pacific through wholesale sales to retailers, e-commerce, and branded stores owned by the company and partners. The company has grown through multiple acquisitions and traces its roots to 1899.
Read more on VFC →
